SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies.
SphingoTec GmbH was established in 2002 by Dr. Andreas Bergmann was one of the founders of B.R.A.H.M.S. AG. As former Chief Research Officer, he was responsible for the development of the “gold standard” sepsis biomarker Procalcitonin (B.R.A.H.M.S. PCT™).
Company Details
- Employees
- 20
- Founded
- -
- Address
- Neuendorfstraße, 15a,germany
- Phone
- +49 33 02/2 05 65-0
- in****@****otec.de
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.sphingotec.com
- HQ
- Hennigsdorf, Brandenburg
Sphingotec Questions
Sphingotec's helpline number is +49 33 02/2 05 65-0
Sphingotec's website is http://www.sphingotec.com
Sphingotec's LinkedIn profile is https://de.linkedin.com/company/sphingotec
Sphingotec has
20 employees.
View email and phone details for 20
employees at Sphingotec.
Sphingotec's industry is
Biotechnology Research
Sphingotec's top competitors are
Thinkcyte,
Migentra Gmbh,
4teen4 Pharmaceuticals,
Cyano Biotech Is Now Simris Biologics,
Invivo Biotech Services Gmbh - A Bruker Company,
Aska Biotech,
Fyonibio Gmbh,
Tme Pharma,
Biogenes Gmbh,
Adrenomed Ag.
Sphingotec's support email address is info@sphingotec.de
Sphingotec's categories are Biotechnology Research
Sphingotec's founding year is 2002
